Note: This document is a translation of a part of the original Japanese version and provided for reference purposes only. In the event of any discrepancy
between the Japanese original and this English translation, the Japanese original shall prevail.

Consolidated Financial Results
for the Year Ended March 31, 2024
[Japanese GAAP]May 14, 2024
Company name: SUNCORPORATION
Stock exchange listing: Tokyo
Code number: 6736
URL: https://www.sun-denshi.co.jp
Representative: Ryusuke Utsumi
President and Representative Director
Contact: Yoshimi Kimura
Representative and Executive managing director
Phone: +81-52-756-5981
Scheduled date of Annual General Meeting of Shareholders: June 25, 2024
Scheduled date of commencing dividend payments: June 26, 2024
Scheduled date of filing annual securities report: June 26, 2024
Availability of supplementary briefing material on annual financial results: Yes
Schedule of annual financial results briefing session: Yes(Amounts of less than one million yen are rounded down.)
1. Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (April 1, 2023 to March 31, 2024)(1) Consolidated Operating Results(% indicates changes from the previous corresponding period.)
Profit attributable toNet sales
Operating profit
Ordinary profit
owners of parent
Millions of yen%
Millions of yen%
Millions of yen%
Millions of yen%
Fiscal year ended
March 31, 2024
10,045(73.2)
312(4,114)(3,777)
March 31, 2023
37,4490.7(1,711)
14,174
46.5
6,878
144.0
(Note) Comprehensive income:Fiscal year ended March 31, 2024:¥3,531 million [(73.9) %]Fiscal year ended March 31, 2023:¥13,510 million [61.3%]
Basic earnings per Diluted earnings per Rate of return onshareshareequity

Ordinary profit tototal assets ratio

Operating profit to
net sales ratio

YenYen%%%Fiscal year ended
March 31, 2024
(169.82)(10.2)(9.3)
3.1
March 31, 2023
292.82278.46
23.2
22.9
(4.6)
(Note: Diluted net income per share for the fiscal year ended March 31, 2024 is not shown in the above table, because net loss per share
was recorded, although there are residual shares.

(2) Consolidated Financial Position
Total assets
As ofMarch 31, 2024
March 31, 2023
(Reference) Equity:

Millions of yen

Net assetsMillions of yen

46,83841,767

Capital adequacy ratio%

Net assets per share
Yen

37,25979.3
1,670.86
35,01383.6
1,542.39
As of March 31, 2024:¥37,157 million
As of March 31, 2023:¥34,908 million(Note: In the consolidated fiscal year ended March 31, 2024, the Company finalized the provisional accounting treatment for thebusiness combination, and the consolidated financial position for the fiscal year ended March 31, 2023 reflects the details of thefinalization of the provisional accounting treatment.

―1―(3) Consolidated Cash Flows
Cash flows fromoperating activities
Fiscal year ended
March 31, 2024
March 31, 2023

Cash flows frominvesting activities

Cash flows fromfinancing activities

Cash and cash
equivalents at the endof period

Millions of yen

Millions of yen

Millions of yen

Millions of yen

2,509(13,518)(3,562)(25,131)(385)
25,574

1,519
2,934

2. Dividends
Annual dividends
1st
2nd
3rd
quarter-end quarter-end quarter-end

Year-end

Total
dividends

Total

Payoutratio(consolidated)

Dividends
to netassets(consolidated)

Fiscal year ended

Yen

YenYen

Yen%%March 31, 2023

-

0.00

-

20.00

20.00

452

6.8

1.6

March 31, 2024

-

0.00

-

40.00

40.00

889

(23.6)

2.5-----

Yen Millions of yen

Fiscal year ending
March 31, 2025-

(Forecast)(Note: The dividend forecast for the fiscal year ending March 31, 2025 is undecided at this time.
3. Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2025 (April 1, 2024 to March 31, 2025)(% indicates changes from the previous corresponding period.)
Net sales

Full year

Operating profit

Millions ofyen%Millions ofyen%12,285

22.29

709

126.66

With regard to the forecast for the year ending 31 March 2025, the impact of recent geopolitical risks and financial instability isuncertain, and it is difficult to reasonably estimate the impact on the Company's results of changes in the fair value of price adjustment
clauses, certain restricted rights shares and derivative warrant liabilities recognised in Cellebrite DI Ltd, an equity method affiliate of theCompany. The impact of changes in the fair value of price adjustment clauses, certain restricted rights shares and derivative warrant
liabilities recognised in Cellebrite DI Ltd. on the Company's results is difficult to reasonably calculate at this stage, and therefore theprofit for each segment below ordinary income has not yet been determined.
* Notes:(1) Changes in significant subsidiaries during the period under review (changes in specified subsidiaries resulting in changes inscope of consolidation): No(2) Changes in accounting policies, changes in accounting estimates and retrospective restatement
1) Changes in accounting policies due to the revision of accounting standards: No
2) Changes in accounting policies other than 1) above: No
3) Changes in accounting estimates: No4) Retrospective restatement: No(3) Total number of issued shares (common shares)
1) Total number of issued shares at the end of the period (including treasury shares):
March 31, 2024:
24,007,728 shares
March 31, 2023:
23,998,828 shares
2) Number of treasury shares at the end of the period:
March 31, 2024:
1,769,277 shares
March 31, 2023:
1,366,387 shares
3) Average number of shares outstanding during the period:
Fiscal Year ended March 31, 2024:
Fiscal Year ended March 31, 2023:

22,245,178 shares
23,490,418 shares―2―(Reference) Summary of Non-consolidated Financial Results
1. Non-consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (April 1, 2023 to March 31, 2024)(1) Non-consolidated Operating Results(% indicates changes from the previous corresponding period.)
Net sales
Fiscal year ended
March 31, 2024
March 31, 2023

Operating profit

Ordinary profit

Net income

Millions of yen%

Millions of yen%

Millions of yen%

Millions of yen%

8,435
8,051

4.8
0.1357
163

118.4
45.5

433
3,415

(87.3)(60.2)

439
3,212(86.3)(86.6)

Basic earnings per share Diluted earnings per share
Fiscal year ended
March 31, 2024
March 31, 2023

Yen

Yen

19.75
136.7819.73
136.55(2) Non-consolidated Financial Position
Total assets
As ofMarch 31, 2024
March 31, 2023
(Reference) Equity:

Net assets

Millions of yen

45,64036,848
As of March 31, 2024:
As of March 31, 2023:

Capital adequacy ratio

Millions of yen¥¥

37,29931,87637,197 million
31,771 million

Net assets per share%

Yen

81.5
86.2

1,672.64
1,403.78*The financial results are not subject to audit by a certified public accountant or auditing firm.
* Explanation of the appropriate use of earnings forecasts and other special notes
With regard to the forecast for the year ending 31 March 2025, the impact of recent geopolitical risks and financial instability
is uncertain, and it is difficult to reasonably estimate the impact on the Company's results of changes in the fair value of priceadjustment clauses, certain restricted rights shares and derivative warrant liabilities recognised in Cellebrite DI Ltd, an equity
method affiliate of the Company. The impact of changes in the fair value of price adjustment clauses, certain restricted rights
shares and derivative warrant liabilities recognised in Cellebrite DI Ltd. on the Company's results is difficult to reasonably
calculate at this stage, and therefore, the profit for the various levels below ordinary income has not yet been determined. For
further details, please refer to page 7, ‘1. Business results (4) Future outlook’.

―3―